<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075110</url>
  </required_header>
  <id_info>
    <org_study_id>0066/2019</org_study_id>
    <nct_id>NCT04075110</nct_id>
  </id_info>
  <brief_title>Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate the safety and efficacy of Montelukast in&#xD;
      treatment of obese patients with type 2 diabetes (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growing evidences have pointed to the role of 5-lipooxygenase / leukotriene pathway in the&#xD;
      pathogenesis of diabesity. Cysteinyl leukotrienes (Cys-LT) are potent inflammatory lipid&#xD;
      mediators derived from the 5-lipoxygenase pathway of arachidonic acid metabolism. They act on&#xD;
      Cys-LT receptors that are primarily present in the spleen, blood leukocytes, and lung&#xD;
      macrophages and are involved in mediation of inflammation. 5-lipoxygenase products exert&#xD;
      potent proinflammatory actions, such as induction of nuclear factor (NF) - kB and secretion&#xD;
      of proinflammatory and insulin resistant adipokines (i.e., monocyte chemotactic protein-1,&#xD;
      tumor necrosis factor-a, macrophage inflammatory protein-1, and interleukin-6) that could&#xD;
      potentially contribute to systemic insulin resistance. Furthermore, the physiological&#xD;
      consequences of these changes in adipose tissue function were corroborated in vivo by the&#xD;
      observation that inhibition of the 5-lipoxygenase pathway reduced proinflammatory cytokines&#xD;
      and circulating free fatty acid concentrations, as well as alleviated insulin resistance and&#xD;
      hepatic steatosis in experimental obesity.&#xD;
&#xD;
      Montelukast is a Cys-LT1-receptor antagonist that blocks the proinflammatory action of LTD4 .&#xD;
      Montelukast is approved for the maintenance treatment of asthma and to relieve symptoms of&#xD;
      seasonal allergies. It acts by inhibiting neutrophil infiltration, balancing&#xD;
      oxidant-antioxidant status, and regulating the generation of inflammatory mediators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>HbA1c</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in body weight</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>Body Weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>body mass index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral Adiposity Index</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>visceral fat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>At baseline to 12 weeks</time_frame>
    <description>Serum level of adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-α</measure>
    <time_frame>At baseline to 12 weeks</time_frame>
    <description>Serum level of Tumor necrosis factor alpha (TNF-α)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>At baseline to 12 weeks</time_frame>
    <description>Serum level of interleukin-6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leukotriene B4</measure>
    <time_frame>At baseline to 12 weeks</time_frame>
    <description>Serum level of leukotriene B4 (LTB4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Obesity; Endocrine; Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 patients will receive metformin 2000mg/daily (Control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients will receive a combination of metformin 2000 mg/daily and montelukast (10 mg /day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast 10mg</intervention_name>
    <description>Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Montelukast group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with&#xD;
        metformin alone and had ages ranging from 18 to 60 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who had any other inflammatory disease&#xD;
&#xD;
          -  patients with cardiovascular,&#xD;
&#xD;
          -  patients with asthma&#xD;
&#xD;
          -  patients with severe hepatic&#xD;
&#xD;
          -  patients with renal disease,&#xD;
&#xD;
          -  patients with epilepsy&#xD;
&#xD;
          -  pregnant or lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Shebin Elkom</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Lecturer of Clinical Pharmacy, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

